Review

mers cov plpro (R&D Systems Hematology)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

R&D Systems Hematology mers cov plpro

a, <t>PLpro</t> proteolytic activity from the supernatant of SARS-CoV-2 or mock infected Calu-3 cells 24 and 48 HPI, measured by the fluorescence of cleaved substrate, normalized across samples from the same day. One-way ANOVA: p=0.014, F(3,8)=6.790; Holm-Šídák’s multiple comparisons, p mock vs. infected 24h =0.244, p mock vs. infected 48h =0.030, n =3 wells per group. b, SARS-CoV-2 transcripts from Calu-3 cells infected with SARS-CoV-2 (multiplicity of infection = 1) for 24 and 48 hours post infection (HPI), transcripts per million (TPM), n =3 wells. c , Interpolated concentration of PLpro in the supernatant of Calu-3 cells 48 hours post infection, line represents mean.

Mers Cov Plpro, supplied by R&D Systems Hematology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mers+cov+plpro/Recombinant+MERS-CoV+His6+Papain-like+Protease+Protein%2C+CF/bio_rxiv__2024__01__10__575114-158-12-14
Average 92 stars, based on 1 article reviews

mers cov plpro - by Bioz Stars, 2026-09

92/100 stars

Images

1) Product Images from "SARS-CoV-2 papain-like protease activates nociceptors to drive sneeze and pain"

Article Title: SARS-CoV-2 papain-like protease activates nociceptors to drive sneeze and pain

Journal: bioRxiv

doi: 10.1101/2024.01.10.575114

a, PLpro proteolytic activity from the supernatant of SARS-CoV-2 or mock infected Calu-3 cells 24 and 48 HPI, measured by the fluorescence of cleaved substrate, normalized across samples from the same day. One-way ANOVA: p=0.014, F(3,8)=6.790; Holm-Šídák’s multiple comparisons, p mock vs. infected 24h =0.244, p mock vs. infected 48h =0.030, n =3 wells per group. b, SARS-CoV-2 transcripts from Calu-3 cells infected with SARS-CoV-2 (multiplicity of infection = 1) for 24 and 48 hours post infection (HPI), transcripts per million (TPM), n =3 wells. c , Interpolated concentration of PLpro in the supernatant of Calu-3 cells 48 hours post infection, line represents mean.

Figure Legend Snippet: a, PLpro proteolytic activity from the supernatant of SARS-CoV-2 or mock infected Calu-3 cells 24 and 48 HPI, measured by the fluorescence of cleaved substrate, normalized across samples from the same day. One-way ANOVA: p=0.014, F(3,8)=6.790; Holm-Šídák’s multiple comparisons, p mock vs. infected 24h =0.244, p mock vs. infected 48h =0.030, n =3 wells per group. b, SARS-CoV-2 transcripts from Calu-3 cells infected with SARS-CoV-2 (multiplicity of infection = 1) for 24 and 48 hours post infection (HPI), transcripts per million (TPM), n =3 wells. c , Interpolated concentration of PLpro in the supernatant of Calu-3 cells 48 hours post infection, line represents mean.

Techniques Used: Activity Assay, Infection, Fluorescence, Concentration Assay

a, Schematic of in vivo imaging preparation. b, Image of trigeminal ganglion overlaid with the regions of interest of neurons that respond to intranasal perfusion (10 µL) of vehicle (Veh), 10 µM PLpro, and 100 µM capsaicin (Cap). c, Representative calcium transients in response to intranasal perfusion of Veh, 10 µM PLpro, 1 mM AITC, 100 µM Cap. d, Venn diagram of neurons responsive to vehicle (112/307) and PLpro (116/307), n =307 neurons from 6 mice. PLpro activates a subset of vehicle-sensitive neurons (32/112). e, Percent of recorded neurons that respond to each stimulus. f, Vehicle and PLpro activate a subset of TRPV1+ (capsaicin-responsive) neurons and TRPA1+ (AITC-responsive) neurons. Top Left, percent of TRPV1+ neurons responsive to vehicle only: 13.8%, both vehicle and PLpro: 9.7%, PLpro only: 15.9%, n =145 neurons from 6 mice; Top Right, percent of TRPV1+ neurons responsive to the first delivery of vehicle only: 17.8%, both first and second (Veh 2 ) deliveries of vehicle: 2.7%, second delivery of vehicle only: 2.7%, n =73 neurons from 3 mice, Chi-square test χ 2 = 112.5, df = 3, p<0.0001. Bottom Left, percent of TRPA1+ neurons responsive to vehicle only: 18.4%, both vehicle and PLpro: 17.2%, PLpro only: 18.4%, n =87 neurons from 4 mice; Bottom Right, percent of TRPA1+ neurons responsive to the first delivery of vehicle only: 25.0%, both deliveries of vehicle: 27.3%, second delivery of vehicle only: 9.1%, n =44 neurons from 3 mice, Chi-square test χ 2 = 14.2, df = 3, p = 0.003.

Figure Legend Snippet: a, Schematic of in vivo imaging preparation. b, Image of trigeminal ganglion overlaid with the regions of interest of neurons that respond to intranasal perfusion (10 µL) of vehicle (Veh), 10 µM PLpro, and 100 µM capsaicin (Cap). c, Representative calcium transients in response to intranasal perfusion of Veh, 10 µM PLpro, 1 mM AITC, 100 µM Cap. d, Venn diagram of neurons responsive to vehicle (112/307) and PLpro (116/307), n =307 neurons from 6 mice. PLpro activates a subset of vehicle-sensitive neurons (32/112). e, Percent of recorded neurons that respond to each stimulus. f, Vehicle and PLpro activate a subset of TRPV1+ (capsaicin-responsive) neurons and TRPA1+ (AITC-responsive) neurons. Top Left, percent of TRPV1+ neurons responsive to vehicle only: 13.8%, both vehicle and PLpro: 9.7%, PLpro only: 15.9%, n =145 neurons from 6 mice; Top Right, percent of TRPV1+ neurons responsive to the first delivery of vehicle only: 17.8%, both first and second (Veh 2 ) deliveries of vehicle: 2.7%, second delivery of vehicle only: 2.7%, n =73 neurons from 3 mice, Chi-square test χ 2 = 112.5, df = 3, p<0.0001. Bottom Left, percent of TRPA1+ neurons responsive to vehicle only: 18.4%, both vehicle and PLpro: 17.2%, PLpro only: 18.4%, n =87 neurons from 4 mice; Bottom Right, percent of TRPA1+ neurons responsive to the first delivery of vehicle only: 25.0%, both deliveries of vehicle: 27.3%, second delivery of vehicle only: 9.1%, n =44 neurons from 3 mice, Chi-square test χ 2 = 14.2, df = 3, p = 0.003.

Techniques Used: In Vivo Imaging

a, Sequential images of a sneeze following intranasal treatment of 10 µM PLpro (10 µL). b, Raster plot of sneezes from individual mice treated with 10 µM PLpro or vehicle identified from audio recordings. c, Average cumulative sneeze count of 10 µM PLpro and vehicle treated mice over 2 minutes d, Sequential images of a nose rub following intranasal treatment e, 10 µM PLpro treated mice display a shorter latency to the first nose rub than vehicle treated mice, t-test: t=2.469, df=29, p=0.020. f, Fraction of mice that elicited a rub and sneeze within the first 30 seconds after treatment. (Vehicle: 9.0%, PLpro (100 nM): 41.7%, PLpro (10 µM): 55.0%). Fisher’s exact test (p vehicle vs. 100nM PLpro =0.252, p vehicle vs. 10µM PLpro =0.020). For all data in this figure, vehicle ( n =11), 100 nM PLpro ( n =12), and 10 µM PLpro ( n =20). Error bars and shading represent the mean ± standard error of the mean (SEM), n = biological replicates (animals).

Figure Legend Snippet: a, Sequential images of a sneeze following intranasal treatment of 10 µM PLpro (10 µL). b, Raster plot of sneezes from individual mice treated with 10 µM PLpro or vehicle identified from audio recordings. c, Average cumulative sneeze count of 10 µM PLpro and vehicle treated mice over 2 minutes d, Sequential images of a nose rub following intranasal treatment e, 10 µM PLpro treated mice display a shorter latency to the first nose rub than vehicle treated mice, t-test: t=2.469, df=29, p=0.020. f, Fraction of mice that elicited a rub and sneeze within the first 30 seconds after treatment. (Vehicle: 9.0%, PLpro (100 nM): 41.7%, PLpro (10 µM): 55.0%). Fisher’s exact test (p vehicle vs. 100nM PLpro =0.252, p vehicle vs. 10µM PLpro =0.020). For all data in this figure, vehicle ( n =11), 100 nM PLpro ( n =12), and 10 µM PLpro ( n =20). Error bars and shading represent the mean ± standard error of the mean (SEM), n = biological replicates (animals).

Techniques Used:

a-c, Sneeze events are identified by audio waveforms and correlate to dye on the bottom of the chamber. a, Representative audio waveform during a sneeze b, Left, images during the same sneeze, arrows indicate dye from the sneeze on the bottom of the chamber. Right, image of dye expulsion from the sneeze event on the bottom of the chamber. c, The number of sneezes over 2 minutes are significantly correlated to the amount of dye at the bottom of the chamber. d, Duration of individual nose rub and face wipe events. e, Image sequence of a nose rub and face wipe. f, Raster plot of rubs, wipes, and body-licking events. g, Average cumulative rub and wipe counts from individual mice treated with 10 µM PLpro ( n =20) or vehicle ( n =11). i-l, Mean and standard error of the sneeze and rub latency and for individual mice treated with j, vehicle ( n =11), k , PLpro (100 nM, n =12), and l , PLpro (10 µM, n =20), n = biological replicates (animals).

Figure Legend Snippet: a-c, Sneeze events are identified by audio waveforms and correlate to dye on the bottom of the chamber. a, Representative audio waveform during a sneeze b, Left, images during the same sneeze, arrows indicate dye from the sneeze on the bottom of the chamber. Right, image of dye expulsion from the sneeze event on the bottom of the chamber. c, The number of sneezes over 2 minutes are significantly correlated to the amount of dye at the bottom of the chamber. d, Duration of individual nose rub and face wipe events. e, Image sequence of a nose rub and face wipe. f, Raster plot of rubs, wipes, and body-licking events. g, Average cumulative rub and wipe counts from individual mice treated with 10 µM PLpro ( n =20) or vehicle ( n =11). i-l, Mean and standard error of the sneeze and rub latency and for individual mice treated with j, vehicle ( n =11), k , PLpro (100 nM, n =12), and l , PLpro (10 µM, n =20), n = biological replicates (animals).

Techniques Used: Sequencing

a, PLpro elicited a shorter latency to the first wipe (One-way ANOVA: p=0.003, F(2,18)=9.983; Tukey’s multiple comparisons, p Veh vs. 10µM PLpro =0.049, p Veh vs. 50µM PLpro =0.003, p 10µM PLpro vs. 50µM PLpro =0.789) and b , a dose-dependent increase in the number of wipes in the first minute. (Kruskal-Wallis: p=0.0116, χ 2 =8.920, Dunn’s multiple comparisons, p Veh vs. 10µM PLpro =0.134, p Veh vs. 50µM PLpro =0.021, p 10µM PLpro vs. 50µM PLpro > 0.999), vehicle ( n =17), PLpro (10 µM, n =5), PLpro (50 µM, n =10). c-d, PLpro does not elicit a shorter latency to scratching or any more scratching than vehicle injection, vehicle ( n =11), PLpro (50 µM, n =10). Error bars represent the mean ± SEM. n = biological replicates (animals).

Figure Legend Snippet: a, PLpro elicited a shorter latency to the first wipe (One-way ANOVA: p=0.003, F(2,18)=9.983; Tukey’s multiple comparisons, p Veh vs. 10µM PLpro =0.049, p Veh vs. 50µM PLpro =0.003, p 10µM PLpro vs. 50µM PLpro =0.789) and b , a dose-dependent increase in the number of wipes in the first minute. (Kruskal-Wallis: p=0.0116, χ 2 =8.920, Dunn’s multiple comparisons, p Veh vs. 10µM PLpro =0.134, p Veh vs. 50µM PLpro =0.021, p 10µM PLpro vs. 50µM PLpro > 0.999), vehicle ( n =17), PLpro (10 µM, n =5), PLpro (50 µM, n =10). c-d, PLpro does not elicit a shorter latency to scratching or any more scratching than vehicle injection, vehicle ( n =11), PLpro (50 µM, n =10). Error bars represent the mean ± SEM. n = biological replicates (animals).

Techniques Used: Injection

a, Representative calcium transients from PLpro responders from cultured neonatal mouse trigeminal ganglia (TG). b, PLpro activates subsets of neurons from adult mouse dorsal root ganglia (DRG; Veh: 2.9%, 1 nM: 4.2%, 10 nM: 6.8%, 100 nM: 11.9%, n =5) and adult mouse nodose and jugular ganglia (NJG; Veh: 5.5%, 1 nM: 21.7%, 10 nM: 23.6%, 100 nM: 33.9%, n =8). c, Venn diagram of PLpro, AITC, and Cap-responsive neurons in DRG and NJG. Of the neurons that respond to these 3 stimuli, Left, in the DRG, 20% responded to PLpro, an additional 48% responded to AITC, and 32% responded to Cap alone. Right, in the NJG, 38% responded to PLpro, an additional 34% responded to AITC, and 28% responded to Cap alone. d, Representative calcium transients evoked by PLpro and capsaicin (Cap) in human iPSC-derived neurons. e, PLpro induces significantly more calcium influx (area under the curve, AUC) than vehicle, t-test: t=2.953, df=6, p=0.026, n =4 wells each. f, Percent of neonatal mouse TG neurons that respond to 250nM PLpro in control neurons from wild-type C57BL/6N mice in physiological extracellular calcium (2 mM Ca 2+ , 5.5%, n =17) is greater than in the absence of extracellular calcium (EGTA, 1.2%, n =3) and in neurons from Trpv1 KO (2.4%, n =27) and Trpa1 KO (1.9%, n =12) mice, and in wild-type mice in the presence of TRPA1 antagonist (HC, 1.7%, n =4). One-way ANOVA: p=0.003, F(4,58)=2.803; Holm-Šídák’s multiple comparisons, p Control vs. EGTA =0.035, p Control vs. Trpv1 KO =0.004, p Control vs. Trpa1 KO =0.004, p Control vs. EGTA =0.035. g-i, SARS-CoV-2 and SARS, but not MERS PLpro activate subsets of neonatal mouse TG neurons in a dose-dependent manner. g , SARS-CoV-2 PLpro: 1nM: 3.8%, 10 nM: 7.2%, 100 nM: 9.3%, n =5. h, SARS PLpro: 1 nM: 1.4%, 10 nM: 3.4%, 100nM: 6.1%, n =5. i, MERS PLpro: 1nM: 1.8%, 10nM: 2.5%, 100nM: 2.7%, n =6. *p <0.05, **p<0.01. Error bars represent the mean ± SEM, n indicates replicates (wells).

Figure Legend Snippet: a, Representative calcium transients from PLpro responders from cultured neonatal mouse trigeminal ganglia (TG). b, PLpro activates subsets of neurons from adult mouse dorsal root ganglia (DRG; Veh: 2.9%, 1 nM: 4.2%, 10 nM: 6.8%, 100 nM: 11.9%, n =5) and adult mouse nodose and jugular ganglia (NJG; Veh: 5.5%, 1 nM: 21.7%, 10 nM: 23.6%, 100 nM: 33.9%, n =8). c, Venn diagram of PLpro, AITC, and Cap-responsive neurons in DRG and NJG. Of the neurons that respond to these 3 stimuli, Left, in the DRG, 20% responded to PLpro, an additional 48% responded to AITC, and 32% responded to Cap alone. Right, in the NJG, 38% responded to PLpro, an additional 34% responded to AITC, and 28% responded to Cap alone. d, Representative calcium transients evoked by PLpro and capsaicin (Cap) in human iPSC-derived neurons. e, PLpro induces significantly more calcium influx (area under the curve, AUC) than vehicle, t-test: t=2.953, df=6, p=0.026, n =4 wells each. f, Percent of neonatal mouse TG neurons that respond to 250nM PLpro in control neurons from wild-type C57BL/6N mice in physiological extracellular calcium (2 mM Ca 2+ , 5.5%, n =17) is greater than in the absence of extracellular calcium (EGTA, 1.2%, n =3) and in neurons from Trpv1 KO (2.4%, n =27) and Trpa1 KO (1.9%, n =12) mice, and in wild-type mice in the presence of TRPA1 antagonist (HC, 1.7%, n =4). One-way ANOVA: p=0.003, F(4,58)=2.803; Holm-Šídák’s multiple comparisons, p Control vs. EGTA =0.035, p Control vs. Trpv1 KO =0.004, p Control vs. Trpa1 KO =0.004, p Control vs. EGTA =0.035. g-i, SARS-CoV-2 and SARS, but not MERS PLpro activate subsets of neonatal mouse TG neurons in a dose-dependent manner. g , SARS-CoV-2 PLpro: 1nM: 3.8%, 10 nM: 7.2%, 100 nM: 9.3%, n =5. h, SARS PLpro: 1 nM: 1.4%, 10 nM: 3.4%, 100nM: 6.1%, n =5. i, MERS PLpro: 1nM: 1.8%, 10nM: 2.5%, 100nM: 2.7%, n =6. *p <0.05, **p<0.01. Error bars represent the mean ± SEM, n indicates replicates (wells).

Techniques Used: Cell Culture, Derivative Assay, Control

PLpro responders are of smaller diameter compared to vehicle responders and the population overall in a. neonatal mouse trigeminal ganglia (Veh: 22.6 µm, PLpro: 15.0 µm, AITC: 15.7 µm, Cap: 16.3 µm, High K+: 16.3 µm) b, adult DRG (Veh: 22.6 µm, PLpro: 16.2 µm, AITC: 22.1 µm, Cap: 19.8 µm, High K+: 21.0 µm) and c, adult NJG neurons (Veh: 22.5 µm, PLpro: 18.2 µm, AITC: 21.4 µm, Cap: 20.9 µm, High K+: 21.5 µm). d, PLpro from independent suppliers R&D Systems (#E-611, 5.5%, n =17) and Cayman (#31817, 5.7%, n =12) display no difference in the percent of responsive neurons in cultured TG, t-test: t=0.13, df=27, p=0.898. Error bars represent the mean ± SEM.

Figure Legend Snippet: PLpro responders are of smaller diameter compared to vehicle responders and the population overall in a. neonatal mouse trigeminal ganglia (Veh: 22.6 µm, PLpro: 15.0 µm, AITC: 15.7 µm, Cap: 16.3 µm, High K+: 16.3 µm) b, adult DRG (Veh: 22.6 µm, PLpro: 16.2 µm, AITC: 22.1 µm, Cap: 19.8 µm, High K+: 21.0 µm) and c, adult NJG neurons (Veh: 22.5 µm, PLpro: 18.2 µm, AITC: 21.4 µm, Cap: 20.9 µm, High K+: 21.5 µm). d, PLpro from independent suppliers R&D Systems (#E-611, 5.5%, n =17) and Cayman (#31817, 5.7%, n =12) display no difference in the percent of responsive neurons in cultured TG, t-test: t=0.13, df=27, p=0.898. Error bars represent the mean ± SEM.

Techniques Used: Cell Culture

a, SARS-CoV-2 viral transcript expression 48 hours after infection in cultured adult trigeminal ganglia, mock infected: n= 4 wells, SARS-CoV-2 infected: n= 3 wells. b, Infection alters gene sets associated with nociception but not mechanoreceptors and proprioceptors. The median absolute log 2 fold change from each custom gene set was tested against 100,000 permutations of randomly selected gene sets of the same size, size of each gene set listed in parenthesis. c, Heatmap of the most highly differentially expressed nociception-associated transcripts (log 2 fold change of infection vs mock). d, PLpro elicits CGRP release from cultured TG. t-test: t=3.928, df=6, p=0.008, n = 4 per group, biological replicates (animal) e, PLpro does not elicit the release of Substance P from cultured TG, One-way ANOVA: p=0.673, F(2,21)=0.215, vehicle ( n =10), 100 nM PLpro ( n =10), and 1 µM PLpro ( n =4) replicates (wells from pooled animals) f, PLpro but not vehicle increases CGRP release from baseline measurements in an ex vivo trachea preparation. Baseline vs. vehicle: one sample t-test: t=0.909, df=5, p=0.405, baseline vs. 1µM PLpro: one sample t-test: t=6.80, df=5, p=0.001, n = 6, biological replicates (animal) per group. *p <0.05, **p<0.01, ***p<0.001. Bar represents mean and error bars represent the mean ± SEM.

Figure Legend Snippet: a, SARS-CoV-2 viral transcript expression 48 hours after infection in cultured adult trigeminal ganglia, mock infected: n= 4 wells, SARS-CoV-2 infected: n= 3 wells. b, Infection alters gene sets associated with nociception but not mechanoreceptors and proprioceptors. The median absolute log 2 fold change from each custom gene set was tested against 100,000 permutations of randomly selected gene sets of the same size, size of each gene set listed in parenthesis. c, Heatmap of the most highly differentially expressed nociception-associated transcripts (log 2 fold change of infection vs mock). d, PLpro elicits CGRP release from cultured TG. t-test: t=3.928, df=6, p=0.008, n = 4 per group, biological replicates (animal) e, PLpro does not elicit the release of Substance P from cultured TG, One-way ANOVA: p=0.673, F(2,21)=0.215, vehicle ( n =10), 100 nM PLpro ( n =10), and 1 µM PLpro ( n =4) replicates (wells from pooled animals) f, PLpro but not vehicle increases CGRP release from baseline measurements in an ex vivo trachea preparation. Baseline vs. vehicle: one sample t-test: t=0.909, df=5, p=0.405, baseline vs. 1µM PLpro: one sample t-test: t=6.80, df=5, p=0.001, n = 6, biological replicates (animal) per group. *p <0.05, **p<0.01, ***p<0.001. Bar represents mean and error bars represent the mean ± SEM.

Techniques Used: Expressing, Infection, Cell Culture, Ex Vivo

a, 50 µM PLpro induces a reduction in the paw withdrawal threshold (PWT) for force 3, but not 24 hours post injection in PLpro injected paws, but not vehicle injected paws compared to baseline. (24 hours pre-injection). Two-way ANOVA: p time = 0.008, F(1.793, 64.56) = 5.477; Holm-Šídák’s multiple comparisons, Veh: p-adjusted Baseline vs. 3 hours =0.361, p-adjusted Baseline vs. 24 hours =0.079; PLpro: p-adjusted Baseline vs. 3 hours =0.008, p-adjusted Baseline vs. 24 hours =0.117, n = 19. b , Wild-type C57BL/6J (WT) and Trpv1 KO mice, but not Trpa1 KO mice develop mechanical hypersensitivity 3 hours post injection. WT: one sample t-test: t=2.746, df=19, p=0.013, n = 11; Trpv1 KO: one sample t-test: t=3.001, df=20, p=0.011, n = 13; Trpa1 KO: one sample t-test: t=0.039, df=10, p=0.970, n = 11. c, 50 µM PLpro injection does not change the latency to respond to the radiant heat stimulation, paired t-test: t=0.233, df=7, p=0.822, n = 8. d, Intranasal treatment of 10 µM PLpro triggers more sneezing in Top Left, WT and Top Right, Trpv1 KO mice than Bottom Right, Trpa1 KO mice or Bottom Left, WT mice treated with vehicle. e, Proposed model: PLpro released from infected cells in the airway epithelium and in the sensory ganglia activate Trpa1-expressing neurons to drive sneeze, pain, and the release of CGRP into the airways. Error bars and shading represent the mean ± standard error of the mean (SEM), n = biological replicates (animals).

Figure Legend Snippet: a, 50 µM PLpro induces a reduction in the paw withdrawal threshold (PWT) for force 3, but not 24 hours post injection in PLpro injected paws, but not vehicle injected paws compared to baseline. (24 hours pre-injection). Two-way ANOVA: p time = 0.008, F(1.793, 64.56) = 5.477; Holm-Šídák’s multiple comparisons, Veh: p-adjusted Baseline vs. 3 hours =0.361, p-adjusted Baseline vs. 24 hours =0.079; PLpro: p-adjusted Baseline vs. 3 hours =0.008, p-adjusted Baseline vs. 24 hours =0.117, n = 19. b , Wild-type C57BL/6J (WT) and Trpv1 KO mice, but not Trpa1 KO mice develop mechanical hypersensitivity 3 hours post injection. WT: one sample t-test: t=2.746, df=19, p=0.013, n = 11; Trpv1 KO: one sample t-test: t=3.001, df=20, p=0.011, n = 13; Trpa1 KO: one sample t-test: t=0.039, df=10, p=0.970, n = 11. c, 50 µM PLpro injection does not change the latency to respond to the radiant heat stimulation, paired t-test: t=0.233, df=7, p=0.822, n = 8. d, Intranasal treatment of 10 µM PLpro triggers more sneezing in Top Left, WT and Top Right, Trpv1 KO mice than Bottom Right, Trpa1 KO mice or Bottom Left, WT mice treated with vehicle. e, Proposed model: PLpro released from infected cells in the airway epithelium and in the sensory ganglia activate Trpa1-expressing neurons to drive sneeze, pain, and the release of CGRP into the airways. Error bars and shading represent the mean ± standard error of the mean (SEM), n = biological replicates (animals).

Techniques Used: Injection, Infection, Expressing

Concentration Assay:

Article Title: SARS-CoV-2 papain-like protease activates nociceptors to drive sneeze and pain
Article Snippet: .. Neurons were stimulated with SARS-CoV-2 PLpro (R&D #E-611), SARS-CoV PLpro (R&D #E-610), MERS-CoV PLpro (R&D #E-609), SARS-CoV-2 PLpro (Cayman #31817) diluted in Ringer’s to the appropriate concentration. ..

Image Search Results

Journal: bioRxiv

Article Title: SARS-CoV-2 papain-like protease activates nociceptors to drive sneeze and pain

doi: 10.1101/2024.01.10.575114

Figure Lengend Snippet: a, PLpro proteolytic activity from the supernatant of SARS-CoV-2 or mock infected Calu-3 cells 24 and 48 HPI, measured by the fluorescence of cleaved substrate, normalized across samples from the same day. One-way ANOVA: p=0.014, F(3,8)=6.790; Holm-Šídák’s multiple comparisons, p mock vs. infected 24h =0.244, p mock vs. infected 48h =0.030, n =3 wells per group. b, SARS-CoV-2 transcripts from Calu-3 cells infected with SARS-CoV-2 (multiplicity of infection = 1) for 24 and 48 hours post infection (HPI), transcripts per million (TPM), n =3 wells. c , Interpolated concentration of PLpro in the supernatant of Calu-3 cells 48 hours post infection, line represents mean.

Article Snippet: Neurons were stimulated with SARS-CoV-2 PLpro (R&D #E-611), SARS-CoV PLpro (R&D #E-610), MERS-CoV PLpro (R&D #E-609), SARS-CoV-2 PLpro (Cayman #31817) diluted in Ringer’s to the appropriate concentration.

Techniques: Activity Assay, Infection, Fluorescence, Concentration Assay

Journal: bioRxiv

Article Title: SARS-CoV-2 papain-like protease activates nociceptors to drive sneeze and pain

doi: 10.1101/2024.01.10.575114

Figure Lengend Snippet: a, Schematic of in vivo imaging preparation. b, Image of trigeminal ganglion overlaid with the regions of interest of neurons that respond to intranasal perfusion (10 µL) of vehicle (Veh), 10 µM PLpro, and 100 µM capsaicin (Cap). c, Representative calcium transients in response to intranasal perfusion of Veh, 10 µM PLpro, 1 mM AITC, 100 µM Cap. d, Venn diagram of neurons responsive to vehicle (112/307) and PLpro (116/307), n =307 neurons from 6 mice. PLpro activates a subset of vehicle-sensitive neurons (32/112). e, Percent of recorded neurons that respond to each stimulus. f, Vehicle and PLpro activate a subset of TRPV1+ (capsaicin-responsive) neurons and TRPA1+ (AITC-responsive) neurons. Top Left, percent of TRPV1+ neurons responsive to vehicle only: 13.8%, both vehicle and PLpro: 9.7%, PLpro only: 15.9%, n =145 neurons from 6 mice; Top Right, percent of TRPV1+ neurons responsive to the first delivery of vehicle only: 17.8%, both first and second (Veh 2 ) deliveries of vehicle: 2.7%, second delivery of vehicle only: 2.7%, n =73 neurons from 3 mice, Chi-square test χ 2 = 112.5, df = 3, p<0.0001. Bottom Left, percent of TRPA1+ neurons responsive to vehicle only: 18.4%, both vehicle and PLpro: 17.2%, PLpro only: 18.4%, n =87 neurons from 4 mice; Bottom Right, percent of TRPA1+ neurons responsive to the first delivery of vehicle only: 25.0%, both deliveries of vehicle: 27.3%, second delivery of vehicle only: 9.1%, n =44 neurons from 3 mice, Chi-square test χ 2 = 14.2, df = 3, p = 0.003.

Techniques: In Vivo Imaging

Journal: bioRxiv

Article Title: SARS-CoV-2 papain-like protease activates nociceptors to drive sneeze and pain

doi: 10.1101/2024.01.10.575114

Figure Lengend Snippet: a, Sequential images of a sneeze following intranasal treatment of 10 µM PLpro (10 µL). b, Raster plot of sneezes from individual mice treated with 10 µM PLpro or vehicle identified from audio recordings. c, Average cumulative sneeze count of 10 µM PLpro and vehicle treated mice over 2 minutes d, Sequential images of a nose rub following intranasal treatment e, 10 µM PLpro treated mice display a shorter latency to the first nose rub than vehicle treated mice, t-test: t=2.469, df=29, p=0.020. f, Fraction of mice that elicited a rub and sneeze within the first 30 seconds after treatment. (Vehicle: 9.0%, PLpro (100 nM): 41.7%, PLpro (10 µM): 55.0%). Fisher’s exact test (p vehicle vs. 100nM PLpro =0.252, p vehicle vs. 10µM PLpro =0.020). For all data in this figure, vehicle ( n =11), 100 nM PLpro ( n =12), and 10 µM PLpro ( n =20). Error bars and shading represent the mean ± standard error of the mean (SEM), n = biological replicates (animals).

Techniques:

Journal: bioRxiv

Article Title: SARS-CoV-2 papain-like protease activates nociceptors to drive sneeze and pain

doi: 10.1101/2024.01.10.575114

Figure Lengend Snippet: a-c, Sneeze events are identified by audio waveforms and correlate to dye on the bottom of the chamber. a, Representative audio waveform during a sneeze b, Left, images during the same sneeze, arrows indicate dye from the sneeze on the bottom of the chamber. Right, image of dye expulsion from the sneeze event on the bottom of the chamber. c, The number of sneezes over 2 minutes are significantly correlated to the amount of dye at the bottom of the chamber. d, Duration of individual nose rub and face wipe events. e, Image sequence of a nose rub and face wipe. f, Raster plot of rubs, wipes, and body-licking events. g, Average cumulative rub and wipe counts from individual mice treated with 10 µM PLpro ( n =20) or vehicle ( n =11). i-l, Mean and standard error of the sneeze and rub latency and for individual mice treated with j, vehicle ( n =11), k , PLpro (100 nM, n =12), and l , PLpro (10 µM, n =20), n = biological replicates (animals).

Techniques: Sequencing

Journal: bioRxiv

Article Title: SARS-CoV-2 papain-like protease activates nociceptors to drive sneeze and pain

doi: 10.1101/2024.01.10.575114

Figure Lengend Snippet: a, PLpro elicited a shorter latency to the first wipe (One-way ANOVA: p=0.003, F(2,18)=9.983; Tukey’s multiple comparisons, p Veh vs. 10µM PLpro =0.049, p Veh vs. 50µM PLpro =0.003, p 10µM PLpro vs. 50µM PLpro =0.789) and b , a dose-dependent increase in the number of wipes in the first minute. (Kruskal-Wallis: p=0.0116, χ 2 =8.920, Dunn’s multiple comparisons, p Veh vs. 10µM PLpro =0.134, p Veh vs. 50µM PLpro =0.021, p 10µM PLpro vs. 50µM PLpro > 0.999), vehicle ( n =17), PLpro (10 µM, n =5), PLpro (50 µM, n =10). c-d, PLpro does not elicit a shorter latency to scratching or any more scratching than vehicle injection, vehicle ( n =11), PLpro (50 µM, n =10). Error bars represent the mean ± SEM. n = biological replicates (animals).

Techniques: Injection

Journal: bioRxiv

Article Title: SARS-CoV-2 papain-like protease activates nociceptors to drive sneeze and pain

doi: 10.1101/2024.01.10.575114

Figure Lengend Snippet: a, Representative calcium transients from PLpro responders from cultured neonatal mouse trigeminal ganglia (TG). b, PLpro activates subsets of neurons from adult mouse dorsal root ganglia (DRG; Veh: 2.9%, 1 nM: 4.2%, 10 nM: 6.8%, 100 nM: 11.9%, n =5) and adult mouse nodose and jugular ganglia (NJG; Veh: 5.5%, 1 nM: 21.7%, 10 nM: 23.6%, 100 nM: 33.9%, n =8). c, Venn diagram of PLpro, AITC, and Cap-responsive neurons in DRG and NJG. Of the neurons that respond to these 3 stimuli, Left, in the DRG, 20% responded to PLpro, an additional 48% responded to AITC, and 32% responded to Cap alone. Right, in the NJG, 38% responded to PLpro, an additional 34% responded to AITC, and 28% responded to Cap alone. d, Representative calcium transients evoked by PLpro and capsaicin (Cap) in human iPSC-derived neurons. e, PLpro induces significantly more calcium influx (area under the curve, AUC) than vehicle, t-test: t=2.953, df=6, p=0.026, n =4 wells each. f, Percent of neonatal mouse TG neurons that respond to 250nM PLpro in control neurons from wild-type C57BL/6N mice in physiological extracellular calcium (2 mM Ca 2+ , 5.5%, n =17) is greater than in the absence of extracellular calcium (EGTA, 1.2%, n =3) and in neurons from Trpv1 KO (2.4%, n =27) and Trpa1 KO (1.9%, n =12) mice, and in wild-type mice in the presence of TRPA1 antagonist (HC, 1.7%, n =4). One-way ANOVA: p=0.003, F(4,58)=2.803; Holm-Šídák’s multiple comparisons, p Control vs. EGTA =0.035, p Control vs. Trpv1 KO =0.004, p Control vs. Trpa1 KO =0.004, p Control vs. EGTA =0.035. g-i, SARS-CoV-2 and SARS, but not MERS PLpro activate subsets of neonatal mouse TG neurons in a dose-dependent manner. g , SARS-CoV-2 PLpro: 1nM: 3.8%, 10 nM: 7.2%, 100 nM: 9.3%, n =5. h, SARS PLpro: 1 nM: 1.4%, 10 nM: 3.4%, 100nM: 6.1%, n =5. i, MERS PLpro: 1nM: 1.8%, 10nM: 2.5%, 100nM: 2.7%, n =6. *p <0.05, **p<0.01. Error bars represent the mean ± SEM, n indicates replicates (wells).

Techniques: Cell Culture, Derivative Assay, Control

Journal: bioRxiv

Article Title: SARS-CoV-2 papain-like protease activates nociceptors to drive sneeze and pain

doi: 10.1101/2024.01.10.575114

Figure Lengend Snippet: PLpro responders are of smaller diameter compared to vehicle responders and the population overall in a. neonatal mouse trigeminal ganglia (Veh: 22.6 µm, PLpro: 15.0 µm, AITC: 15.7 µm, Cap: 16.3 µm, High K+: 16.3 µm) b, adult DRG (Veh: 22.6 µm, PLpro: 16.2 µm, AITC: 22.1 µm, Cap: 19.8 µm, High K+: 21.0 µm) and c, adult NJG neurons (Veh: 22.5 µm, PLpro: 18.2 µm, AITC: 21.4 µm, Cap: 20.9 µm, High K+: 21.5 µm). d, PLpro from independent suppliers R&D Systems (#E-611, 5.5%, n =17) and Cayman (#31817, 5.7%, n =12) display no difference in the percent of responsive neurons in cultured TG, t-test: t=0.13, df=27, p=0.898. Error bars represent the mean ± SEM.

Techniques: Cell Culture

Journal: bioRxiv

Article Title: SARS-CoV-2 papain-like protease activates nociceptors to drive sneeze and pain

doi: 10.1101/2024.01.10.575114

Figure Lengend Snippet: a, SARS-CoV-2 viral transcript expression 48 hours after infection in cultured adult trigeminal ganglia, mock infected: n= 4 wells, SARS-CoV-2 infected: n= 3 wells. b, Infection alters gene sets associated with nociception but not mechanoreceptors and proprioceptors. The median absolute log 2 fold change from each custom gene set was tested against 100,000 permutations of randomly selected gene sets of the same size, size of each gene set listed in parenthesis. c, Heatmap of the most highly differentially expressed nociception-associated transcripts (log 2 fold change of infection vs mock). d, PLpro elicits CGRP release from cultured TG. t-test: t=3.928, df=6, p=0.008, n = 4 per group, biological replicates (animal) e, PLpro does not elicit the release of Substance P from cultured TG, One-way ANOVA: p=0.673, F(2,21)=0.215, vehicle ( n =10), 100 nM PLpro ( n =10), and 1 µM PLpro ( n =4) replicates (wells from pooled animals) f, PLpro but not vehicle increases CGRP release from baseline measurements in an ex vivo trachea preparation. Baseline vs. vehicle: one sample t-test: t=0.909, df=5, p=0.405, baseline vs. 1µM PLpro: one sample t-test: t=6.80, df=5, p=0.001, n = 6, biological replicates (animal) per group. *p <0.05, **p<0.01, ***p<0.001. Bar represents mean and error bars represent the mean ± SEM.

Techniques: Expressing, Infection, Cell Culture, Ex Vivo

Journal: bioRxiv

Article Title: SARS-CoV-2 papain-like protease activates nociceptors to drive sneeze and pain

doi: 10.1101/2024.01.10.575114

Figure Lengend Snippet: a, 50 µM PLpro induces a reduction in the paw withdrawal threshold (PWT) for force 3, but not 24 hours post injection in PLpro injected paws, but not vehicle injected paws compared to baseline. (24 hours pre-injection). Two-way ANOVA: p time = 0.008, F(1.793, 64.56) = 5.477; Holm-Šídák’s multiple comparisons, Veh: p-adjusted Baseline vs. 3 hours =0.361, p-adjusted Baseline vs. 24 hours =0.079; PLpro: p-adjusted Baseline vs. 3 hours =0.008, p-adjusted Baseline vs. 24 hours =0.117, n = 19. b , Wild-type C57BL/6J (WT) and Trpv1 KO mice, but not Trpa1 KO mice develop mechanical hypersensitivity 3 hours post injection. WT: one sample t-test: t=2.746, df=19, p=0.013, n = 11; Trpv1 KO: one sample t-test: t=3.001, df=20, p=0.011, n = 13; Trpa1 KO: one sample t-test: t=0.039, df=10, p=0.970, n = 11. c, 50 µM PLpro injection does not change the latency to respond to the radiant heat stimulation, paired t-test: t=0.233, df=7, p=0.822, n = 8. d, Intranasal treatment of 10 µM PLpro triggers more sneezing in Top Left, WT and Top Right, Trpv1 KO mice than Bottom Right, Trpa1 KO mice or Bottom Left, WT mice treated with vehicle. e, Proposed model: PLpro released from infected cells in the airway epithelium and in the sensory ganglia activate Trpa1-expressing neurons to drive sneeze, pain, and the release of CGRP into the airways. Error bars and shading represent the mean ± standard error of the mean (SEM), n = biological replicates (animals).

Techniques: Injection, Infection, Expressing

( A ) SDS-PAGE 10% analysis of small-scale expression for the MERS-PLpro with poly His-tag of E. coli BL21(DE3) molecular weights for MERS-PLpro: 37. kDa. M = Precision Plus Protein TM all blue standard protein marker from BioRad, lane 1 = crude extract, lane 2 = flowthrough, lane 3 = elution after 10 mM imidazole wash, lane 4 = blank, lane 5 = crude extract, lane 6 = flowthrough, lane 7 elution after 30 mM imidazole wash. ( B ). Western blot M = Precision Plus Protein TM all blue standard protein marker from BioRad, lane 1 = crude extract, lane 2 = elution after 30 mM imidazole wash.

Journal: Molecules

Article Title: Identification of Doxorubicin as Repurposing Inhibitory Drug for MERS-CoV PLpro

doi: 10.3390/molecules27217553

Figure Lengend Snippet: ( A ) SDS-PAGE 10% analysis of small-scale expression for the MERS-PLpro with poly His-tag of E. coli BL21(DE3) molecular weights for MERS-PLpro: 37. kDa. M = Precision Plus Protein TM all blue standard protein marker from BioRad, lane 1 = crude extract, lane 2 = flowthrough, lane 3 = elution after 10 mM imidazole wash, lane 4 = blank, lane 5 = crude extract, lane 6 = flowthrough, lane 7 elution after 30 mM imidazole wash. ( B ). Western blot M = Precision Plus Protein TM all blue standard protein marker from BioRad, lane 1 = crude extract, lane 2 = elution after 30 mM imidazole wash.

Article Snippet: Codon-optimized and synthesized by GenScript, the MERS-CoV PLpro sequence (GenBank accession number AFS88944) was then cloned into pET28b+ with NcoI and XhoI carrying a C-terminal His-tag.

Techniques: SDS Page, Expressing, Marker, Western Blot

Percentage inhibition of MERS-CoV PLpro activity as a function of doxorubicin log concentration ( A ). Percentage inhibition for dose–response curve ( B ). Dose–response curve of MERS-CoV PLpro inhibition identified from the IC 50 protease inhibition assay with dissociation of Z-RLRGG-AMC substrate. Values represent the average ± standard deviation of three replicates.

Journal: Molecules

Article Title: Identification of Doxorubicin as Repurposing Inhibitory Drug for MERS-CoV PLpro

doi: 10.3390/molecules27217553

Figure Lengend Snippet: Percentage inhibition of MERS-CoV PLpro activity as a function of doxorubicin log concentration ( A ). Percentage inhibition for dose–response curve ( B ). Dose–response curve of MERS-CoV PLpro inhibition identified from the IC 50 protease inhibition assay with dissociation of Z-RLRGG-AMC substrate. Values represent the average ± standard deviation of three replicates.

Techniques: Inhibition, Activity Assay, Concentration Assay, Standard Deviation

Journal: Molecules

Article Title: Identification of Doxorubicin as Repurposing Inhibitory Drug for MERS-CoV PLpro

doi: 10.3390/molecules27217553

Figure Lengend Snippet: Melting temperature (Tm) of MERS-CoV-2 PLpro by thermal shift assay (TSA). Figure plotted by TSA-CRAFT. Raw data represented with plus sign (light blue) and fitted data with dashed line (light red). Representative images of Tm of MERS-CoV PLpro profile with DOX at different concentrations ( A , B ). The melting temperature of MERS-CoV-2 PLpro only ( C ) and with acyclovir showed similar melting temperatures ( D ).

Techniques: Thermal Shift Assay, CRAfT Assay

Binding site of doxorubicin (white) with MERS-CoV PLpro surface representation (dark gray) ( a ). In ( b ), enlargement of the PLpro–doxorubicin interaction and PLpro residues are noted in gray and dashed yellow line indicate hydrogen bonds. Doxorubicin in white, small box on the left for 2D doxorubicin. Three hydrogen bonds formed between DOX and PLpro indicated with yellow dashed line.

Journal: Molecules

Article Title: Identification of Doxorubicin as Repurposing Inhibitory Drug for MERS-CoV PLpro

doi: 10.3390/molecules27217553

Figure Lengend Snippet: Binding site of doxorubicin (white) with MERS-CoV PLpro surface representation (dark gray) ( a ). In ( b ), enlargement of the PLpro–doxorubicin interaction and PLpro residues are noted in gray and dashed yellow line indicate hydrogen bonds. Doxorubicin in white, small box on the left for 2D doxorubicin. Three hydrogen bonds formed between DOX and PLpro indicated with yellow dashed line.

Techniques: Binding Assay

MERS-CoV PLpro MD simulation results. In ( a ), C-α root-mean-square deviation (C-α RMSD) as a function of time (ps) is plotted. C-α RMSD showed a stable system during the 100 ns-run simulations. ( b ) The C-α root-mean-square fluctuation (C-α RMSF) plotted against PLpro residues showed flexible residues and regions.

Journal: Molecules

Article Title: Identification of Doxorubicin as Repurposing Inhibitory Drug for MERS-CoV PLpro

doi: 10.3390/molecules27217553

Figure Lengend Snippet: MERS-CoV PLpro MD simulation results. In ( a ), C-α root-mean-square deviation (C-α RMSD) as a function of time (ps) is plotted. C-α RMSD showed a stable system during the 100 ns-run simulations. ( b ) The C-α root-mean-square fluctuation (C-α RMSF) plotted against PLpro residues showed flexible residues and regions.

Techniques:

Review

mers cov plpro (R&D Systems Hematology)

Structured Review

Images

1) Product Images from "SARS-CoV-2 papain-like protease activates nociceptors to drive sneeze and pain"

Related Articles

Concentration Assay:

Similar Products

Image Search Results